SESSION #1 WITH HEALTHCARE PROFESSIONALS
» The DMT Armamentarium: Open Access vs. Precision Medicine
» Mental Health in the MS Patient: What Takes Priority?
» Does the Patient Know Best? An Examination of Two Decision -Making Perspectives
SESSION #2 WITH PEOPLE LIVING WITH MS OR AFFECTED BY MS (NO CEUs OFFERED)
» DMTs in MS: Choices and Challenges
» Symptomatic Care in MS
» Psychosocial Issues and How Nursing Professionals Can Help
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and the International Organization of Multiple Sclerosis Nurses (IOMSN). CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit Designation Statement:
The CMSC designates this activity for a maximum of 3.0 contact hours of continuing nursing education (1.0 of these credits are in the area of pharmacology).
The target audience for this activity is nursing professionals involved in the management of patients with MS.
At the conclusion of this activity, learners should be better able to:
• Incorporate accumulated evidence, current guidelines, and emerging new clinical data into individualized education regarding DMTs for MS as part of a comprehensive approach to nursing care
• Identify and address symptoms experienced by patients with MS, with attention to patient values and goals for pharmacologic and non-pharmacologic treatment
• Integrate a multidisciplinary team approach to care that includes patients and their care partners recognizing, assessing, and addressing psychological and cognitive issues in MS
Disclosure of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, the Consortium of Multiple Sclerosis Centers (CMSC) and the International Organization of Multiple Sclerosis Nurses (IOMSN) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC and IOMSN resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and IOMSN seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and IOMSN are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN, has disclosed the following relevant financial relationships: Consulting Fees: Biogen, Bristol Myers Squibb, Genentech, Roche, Sanofi Genzyme, and Viela Bio; Advisory Board: Bristol Myers Squibb, Genentech, Roche, Sanofi Genzyme, and Viela Bio.
Denise Bruen, ANP-BC, MSN, MSCN, has disclosed the following relevant financial relationships: Consulting Fees: Biogen, Celgene, EMD Serono, Genentech.
Marie Namey, APRN, MSCN, has disclosed the following relevant financial relationships: Consulting Fees: Genentech, Novartis, and Viela Bio; Advisory Board: Biogen, EMD Serono, Genentech, Novartis, and Viela Bio.
Planning Committee Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, has disclosed no relevant financial relationships.
Colleen Harris, MN, NP, MSCN, has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, Novartis, Roche, and Sanofi Genzyme.
Laurie Scudder, DNP, NP, has served as Reviewer for this activity and has disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, or other members at CMSC and IOMSN who are in a position to control content have declared that they have no relevant financial relationships.
CMSC and IOMSN present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and IOMSN, and the commercial supporters assume no liability for the information herein.
There is no fee to participate in this activity.
This activity is supported by educational grants received from Biogen, Bristol Myers Squibb and Genentech.
This activity is supported by educational grants received from Biogen, Bristol Myers Squibb, Genentech and Novartis.